Pasithea Therapeutics Corp. has announced the successful enrollment and initial dosing of three subjects in Cohort 6 of its Phase 1 clinical trial for PAS-004, a candidate for treating ...
Verastem, Inc. (NASDAQ:VSTM) is one of the top long-term biotechnology stocks to buy. On October 23, Verastem, Inc. (NASDAQ:VSTM) reported positive preliminary results from an ongoing phase 1/2a ...
Psoriasis is characterized by hyperproliferation of keratinocytes and increased expression of integrins, but the pathological signaling pathway remains unknown. In August 15 Journal of Clinical ...
A phase I/II, first-in-human study of VLS-1488, an oral KIF18A inhibitor, in patients with advanced cancer. Background: Bromodomain and extra-terminal (BET) proteins serve as epigenetic readers and ...
TipRanks on MSN
Verastem Reports Promising Phase 1/2a Trial Data
Verastem ( ($VSTM) ) just unveiled an announcement. On October 23, 2025, Verastem announced preliminary data from its ongoing Phase 1/2a trial of ...
Phase 1 study of zavondemstat (TACH101), a first-in-class KDM4 inhibitor, in patients with advanced solid tumors: Results on safety, pharmacokinetics, and anti-tumor activity. Pertuzumab plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback